Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 2/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12947550 | 0.97 | MMP2 (0.63) | MMP2GNAI3GNAO1GNAI1TLR2 | |
| Lisdexamfetamine SCHEMBL678421 | 0.94 | MMP2 (0.59) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL970534 | 0.94 | MMP2 (0.59) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL29124173 | 0.94 | MMP2 (0.59) | MMP2THRBNPC1RAB9AANPEP | |
| SCHEMBL972177 | 0.90 | MMP2 (0.48) | MMP2NPC1RAB9AANPEPRNPEP | |
| Lisdexamfetamine SCHEMBL7919487 | 0.90 | MMP2 (0.64) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL12947679 | 0.90 | MMP2 (0.64) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL158949 | 0.90 | MMP2 (0.64) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL31173641 | 0.90 | MMP2 (0.64) | MMP2THRBNPC1RAB9AANPEP | |
| Lisdexamfetamine SCHEMBL579061 | 0.90 | MMP2 (0.64) | MMP2THRBNPC1RAB9AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-7659253-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090234002-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234002-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885GNAI3 1761/4885GNAO1 850/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885GNAI3 1761/4885GNAO1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.